shutterstock_775583896 CART.jpg

Study Single-Cell Interactions with

Unprecedented Throughput and Precision

Scribe Biosciences is an early-stage company pioneering technologies to accelerate immunotherapy discoveries through linked functional and genomic profiling of single-cell interactions. 

 
Screen Shot 2020-07-07 at 8.10.25 PM.png

Technology

  • Scribe Biosciences was established from technologies developed at the University of California, San Francisco to build droplet microfluidic assays with precise cell ratios.

  • Scribe's core technology, Microenvironment on Demand (MOD), enables the construction of hundreds of thousands of live cell-based assays (cytotoxicity, secretion) in droplets and selectively profile assay-positive droplets using genomics readouts.

  • MOD will enable deeper understanding of cancer, heart and autoimmune diseases by linking live-cell assays to genomics at a single-cell resolution.

 
 

Team

image0_edited_edited.jpg
Russell Cole, PhD
CEO/Co-Founder
Ian Walton
Sr. VP of Engineering
Zev Gartner, PhD
Advisor/Co-Founder
Adam Abate, PhD
Advisor/Co-Founder
Justin Madrigal, PhD
Sr. Scientist
Nathan Schoepp, PhD
Sr. Scientist
Paul McEwan
Investor
Lawrence Fong, MD
Scientific Advisor
Maithreyan Srinivasan, PhD
Advisor/Co-Founder
Codian Powell, M.S.
Associate Scientist
 
 

Job Opportunities

Screen Shot 2020-07-15 at 3.29.25 PM.png

953 Indiana St.

San Francisco, CA 94107 

Email: info@scribebiosciences.com

Please drop us a line. We are actively seeking out collaboration and pilot project opportunities.